drugset / Trial / NCT05013697

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

NCT05013697

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The regimen of paclitaxel+cisplatin+TQB2450 injection combined or not combined with anlotinib is the first-line treatment of advanced esophageal squamous cell carcinoma. Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness and safety

Timeline

Start
2021-09
Primary completion
2022-12-31
Completion
2023-07-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Benmelstobart Monoclonal antibody 1200 mg Intravenous
Subject Catequentinib Small molecule 10 mg Oral
Background Cisplatin Other / unclassified 60 mg/m2 Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Paclitaxel Small molecule 135 mg/m2 Intravenous

Indications